肿瘤患者不规则抗体筛查分析  

Irregular antibody screening analysis of tumor patients

作　　者：张学慧[1] 王晨[1] 樊晶[2] 

机构地区：[1]天津医科大学附属肿瘤医院 天津市肿瘤防治重点实验室,天津300060 [2]天津市血液中心

出　　处：《中国输血杂志》2014年第1期27-29,共3页Chinese Journal of Blood Transfusion

摘　　要：目的了解肿瘤患者红细胞血型不规则抗体的分布特点，确保输血安全。方法用微柱凝胶抗球蛋白法筛查不规则抗体，对不规则抗体筛查阳性患者进行抗体特异性鉴定、Ig类型区分及效价测定。结果2500名肿瘤住院患者中共检出不规则抗体27例，阳性检出率为1．10％，其中Rh系统抗体占51．85％、P系统抗体占7．41％、MN系统抗体占14．81％、Kidd系统抗体占3．70％、ABO亚型抗体占3．70％以及自身抗体占18．52％，检出的不规则抗体效价在8—64，以IgG类抗体为主。结论对肿瘤患者检测不规则抗体，有利于保障临床用血，降低溶血性输血反应的发生。Objective To explore the distribution of irregular antibodies in tumor patients and to ensure the safety of blood transfusion. Methods The patients＇ irregular antibodies were screened with micro-column gel card technique, and then determine the type of the antibody and the antibody fiter. Results In 2 500 cases of tumor patients, we got 27 cases with irregular antibodies. The positive rate was 1.10% ,in which 51.85% with antibodies in Rh system,7.41% in P system, 14.81% in MN system,3.70% in Kidd system,3.70% in ABO system, 18.52% in antoantibody system. The titer of irregular antibody was 8 to 64 and the majority of the antibody was IgG subtype. Conclusion The screening of irregular antibodies in tumor patients helps to guarantee the safety of blood transfusion in operation and reduce the possibility of hemolytic transfusion reaction.

关 键 词：肿瘤 不规则抗体 溶血性输血反应 

分 类 号：R457.11[医药卫生—治疗学]